Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14729MR)

This product GTTS-WQ14729MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14729MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15851MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ8136MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ774MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ6705MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ5363MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ6036MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ12813MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ3108MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW